WO1994003620A3 - Procede permettant d'accroitre l'expression de proteines virales - Google Patents

Procede permettant d'accroitre l'expression de proteines virales Download PDF

Info

Publication number
WO1994003620A3
WO1994003620A3 PCT/US1993/007299 US9307299W WO9403620A3 WO 1994003620 A3 WO1994003620 A3 WO 1994003620A3 US 9307299 W US9307299 W US 9307299W WO 9403620 A3 WO9403620 A3 WO 9403620A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral proteins
increasing expression
proteins
methods
cell
Prior art date
Application number
PCT/US1993/007299
Other languages
English (en)
Other versions
WO1994003620A2 (fr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to MX9400188A priority Critical patent/MX9400188A/es
Priority to EP93918614A priority patent/EP0652966B1/fr
Priority to DE69332334T priority patent/DE69332334T2/de
Priority to JP6505519A priority patent/JP3048387B2/ja
Priority to DK93918614T priority patent/DK0652966T3/da
Priority to CA002140531A priority patent/CA2140531C/fr
Priority to AU48008/93A priority patent/AU680425B2/en
Priority to AT93918614T priority patent/ATE224956T1/de
Publication of WO1994003620A2 publication Critical patent/WO1994003620A2/fr
Publication of WO1994003620A3 publication Critical patent/WO1994003620A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Abstract

Procédés d'expression et de sécrétion par recombinaison de protéines virales. Ces procédés consistent à utiliser des agents accompagnateurs compatibles afin d'entraîner les protéines en un mouvement de navette vers la surface cellulaire. De cette façon, la sortie de protéines produites par recombinaison de la cellule est facilitée, ce qui permet d'obtenir des rendements accrus et une purification plus aisée de la protéine requise.
PCT/US1993/007299 1992-07-29 1993-07-29 Procede permettant d'accroitre l'expression de proteines virales WO1994003620A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MX9400188A MX9400188A (es) 1993-07-29 1993-07-29 Metodo para producir en forma recombinante una proteina y complejo quecomprende dicha proteina.
EP93918614A EP0652966B1 (fr) 1992-07-29 1993-07-29 Procede permettant d'accroitre l'expression de proteines virales
DE69332334T DE69332334T2 (de) 1992-07-29 1993-07-29 Verfahren zur verstärkten expression von virusproteinen
JP6505519A JP3048387B2 (ja) 1992-07-29 1993-07-29 ウイルスタンパク質の発現を増大する方法
DK93918614T DK0652966T3 (da) 1992-07-29 1993-07-29 Fremgangsmåde til forøgelse af ekspression af virale proteiner
CA002140531A CA2140531C (fr) 1992-07-29 1993-07-29 Methode pour augmenter l'expression de proteines virales
AU48008/93A AU680425B2 (en) 1992-07-29 1993-07-29 Method of increasing expression of viral proteins
AT93918614T ATE224956T1 (de) 1992-07-29 1993-07-29 Verfahren zur verstärkten expression von virusproteinen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/921,807 1992-07-29
US07/921,807 US5474914A (en) 1992-07-29 1992-07-29 Method of producing secreted CMV glycoprotein H

Publications (2)

Publication Number Publication Date
WO1994003620A2 WO1994003620A2 (fr) 1994-02-17
WO1994003620A3 true WO1994003620A3 (fr) 1994-05-11

Family

ID=25446002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/007299 WO1994003620A2 (fr) 1992-07-29 1993-07-29 Procede permettant d'accroitre l'expression de proteines virales

Country Status (9)

Country Link
US (2) US5474914A (fr)
EP (2) EP1298215A3 (fr)
JP (1) JP3048387B2 (fr)
AT (1) ATE224956T1 (fr)
AU (1) AU680425B2 (fr)
CA (1) CA2140531C (fr)
DE (1) DE69332334T2 (fr)
DK (1) DK0652966T3 (fr)
WO (1) WO1994003620A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242567B1 (en) * 1984-07-27 2001-06-05 City Of Hope Method for detection and prevention of human cytomegalovirus infection
US6162620A (en) * 1986-03-07 2000-12-19 Cogent Limited Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
US6855316B1 (en) * 1994-02-14 2005-02-15 University Of Hawaii Baculovirus produced Plasmodium falciparum vaccine
US5470719A (en) * 1994-03-18 1995-11-28 Meng; Shi-Yuan Modified OmpA signal sequence for enhanced secretion of polypeptides
MY114769A (en) * 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220
US5807557A (en) * 1994-07-25 1998-09-15 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex
US6156319A (en) * 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
US5742181A (en) * 1996-06-04 1998-04-21 Hewlett-Packard Co. FPGA with hierarchical interconnect structure and hyperlinks
US6461814B1 (en) * 1997-01-15 2002-10-08 Dominic G. Spinella Method of identifying gene transcription patterns
WO2000039311A1 (fr) * 1998-12-31 2000-07-06 Advanced Research And Technology Institute Recepteur humain du facteur de croissance des fibroblastes utilise comme co-recepteur dans l'injection du virus 2 associe aux adenovirus
US6710173B1 (en) * 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
US7108984B2 (en) * 2000-01-12 2006-09-19 Mount Sinai School Of Medicine Methods of identifying modulators of the FGF receptor
US20030100106A1 (en) * 2000-02-08 2003-05-29 Chang Sandra P. Baculovirus produced Plasmodium falciparum vaccine
US7015033B1 (en) * 2000-05-25 2006-03-21 Aventis Pasteur Limited Co-expression of recombination proteins
JP2005502350A (ja) * 2001-09-06 2005-01-27 プロジェニクス・ファーマスーティカルズ・インコーポレイテッド ヒト免疫不全ウイルスエンベロープ糖タンパク質変異体およびその使用
US20030199092A1 (en) * 2002-01-11 2003-10-23 The Regents Of The University Of California Methods for increasing mRNA half-life in eukaryotic cells
US20060051373A1 (en) * 2002-04-05 2006-03-09 Olson William C Particle-bound human immunodeficiency virus envelope glycoproteins and related compositions and methods
US7601491B2 (en) 2003-02-06 2009-10-13 Becton, Dickinson And Company Pretreatment method for extraction of nucleic acid from biological samples and kits therefor
US20080274134A1 (en) * 2004-06-15 2008-11-06 Norbert Schulke Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex
WO2006017724A1 (fr) * 2004-08-06 2006-02-16 Becton, Dickinson And Company Sequences et procedes pour la detection de cytomegalovirus
WO2007014123A2 (fr) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions et procedes de traitement de maladies a l'aide de proteines de fusion fgfr
EP2040747A4 (fr) * 2006-06-19 2010-08-25 Progenics Pharm Inc Protéines env vih trimériques solubles stabilisées et leurs utilisations
CA2667358A1 (fr) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Polypeptides d'enveloppe gp140 modifies en provenance d'isolats du vih-1, compositions, complexes trimeriques et utilisations de ceux-ci
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EP2318529B1 (fr) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Mutéines de la région acide du domaine extracellulaire de FGFR.
US9279013B2 (en) 2008-10-10 2016-03-08 Amgen Inc. FGF-21 mutants comprising polyethylene glycol and uses thereof
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
CN107188950B (zh) 2009-05-05 2021-09-28 安姆根有限公司 Fgf21突变体及其用途
WO2011034940A1 (fr) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Méthodes de croissance des cheveux utilisant les domaines extracellulaires de fgfr4
ES2600631T3 (es) 2009-11-13 2017-02-10 Five Prime Therapeutics, Inc. Uso de proteínas del dominio extracelular de FGFR1 para tratar cánceres caracterizados por mutaciones activadoras dependientes de ligando en FGFR2
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
EP3187585A1 (fr) 2010-03-25 2017-07-05 Oregon Health&Science University Glycoprotéines de cytomégalovirus (cmv) et vecteurs de recombinaison
WO2012006369A2 (fr) 2010-07-06 2012-01-12 Novartis Ag Immunisation de grands mammifères à l'aide de faibles doses d'arn
ES2770335T3 (es) 2010-07-06 2020-07-01 Glaxosmithkline Biologicals Sa Administración de ARN para desencadenar múltiples vías inmunológicas
PL2590626T3 (pl) 2010-07-06 2016-04-29 Glaxosmithkline Biologicals Sa Liposomy z lipidami o korzystnej wartości pka do dostarczania rna
LT3981427T (lt) 2010-08-31 2022-08-10 Glaxosmithkline Biologicals S.A. Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
MX363307B (es) 2010-10-11 2019-03-20 Novartis Ag Star Plataformas para suministro de antigenos.
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
EP2502631A1 (fr) * 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immunosuppresseur et son utilisation
CA2840989A1 (fr) 2011-07-06 2013-01-10 Novartis Ag Compositions de combinaisons immunogenes et utilisations de celles-ci
BR112014008694A2 (pt) 2011-10-11 2017-06-20 Novartis Ag moléculas de ácido nucleico policistrônico recombinante
CA2855818A1 (fr) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. Methode de traitement du cancer du poumon comprenant l'amplification du gene fgfr1 ou sa surexpression
SG11201408328VA (en) * 2012-07-06 2015-02-27 Novartis Ag Complexes of cytomegalovirus proteins
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN108300731A (zh) * 2018-02-02 2018-07-20 暨南大学 含有人巨细胞病毒ul115基因的重组质粒、基因工程菌及其应用
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0319944A2 (fr) * 1987-12-08 1989-06-14 Zymogenetics, Inc. Co-expression dans des cellules eucaryotes
WO1992002628A1 (fr) * 1990-08-02 1992-02-20 Chiron Corporation Expression de glycoproteine-h de cytomegalovirus humain utilisant le systeme d'expression cellulaire de baculovirus-insectes
WO1992006212A1 (fr) * 1990-09-28 1992-04-16 Smithkline Beecham Corporation Expression amelioree de proteines virales dans des cellules de drosophila
EP0509841A2 (fr) * 1991-04-18 1992-10-21 Tonen Corporation Système de co-expression d'un gène de la protéine disolfure isomerase et d'un gène d'un polypeptide utile et procédé de production de ce polypeptide en utilisant un tel système
WO1993011248A1 (fr) * 1991-11-29 1993-06-10 Ciba-Geigy Ag Production de proteines au moyen de la proteine 7b2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0163441B1 (ko) * 1989-11-17 1998-12-01 로버트 에이 아미테이지 트리시클릭[6,5,5]/[6,6,5]-융합 옥사졸리디논 항균제

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0319944A2 (fr) * 1987-12-08 1989-06-14 Zymogenetics, Inc. Co-expression dans des cellules eucaryotes
WO1992002628A1 (fr) * 1990-08-02 1992-02-20 Chiron Corporation Expression de glycoproteine-h de cytomegalovirus humain utilisant le systeme d'expression cellulaire de baculovirus-insectes
WO1992006212A1 (fr) * 1990-09-28 1992-04-16 Smithkline Beecham Corporation Expression amelioree de proteines virales dans des cellules de drosophila
EP0509841A2 (fr) * 1991-04-18 1992-10-21 Tonen Corporation Système de co-expression d'un gène de la protéine disolfure isomerase et d'un gène d'un polypeptide utile et procédé de production de ce polypeptide en utilisant un tel système
WO1993011248A1 (fr) * 1991-11-29 1993-06-10 Ciba-Geigy Ag Production de proteines au moyen de la proteine 7b2

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HEINWEMAN, T. ET AL.: "Identification of the Epstein-Barr virus gp85 gene", JOURNAL OF VIROLOGY, vol. 62, no. 4, April 1988 (1988-04-01), pages 1101 - 1107 *
HUTCHINSON, L. ET AL.: "A novel herpes simplex virus glycoprotein, gL forms a complex with glycoprotein H (gH) and affects normal folding and surface expression of gH", JOURNAL OF VIROLOGY, vol. 66, no. 4, April 1992 (1992-04-01), pages 2240 - 2250 *
KAUFMAN, R.J. ET AL.: "Effect of von Willebrand factor coexpression on the synthesis and secretion of Factor VIII in Chinese Hamster Ovary cells", MOLECULAR AND CELLULAR BIOLOGY, vol. 9, no. 3, March 1989 (1989-03-01), pages 1233 - 1242 *
KAYE, J.F. ET AL.: "Glycoprotein H of human cytomegalovirus (HCMV) forms a stable complex with the HCMV UL115 gene product", JOURNAL OF GENERAL VIROLOGY, vol. 73, no. 10, October 1992 (1992-10-01), pages 2693 - 2698 *
SAMBROOK, J. & GETHING, M.J.: "Chaperones, paperones", NATURE., vol. 342, 16 November 1989 (1989-11-16), LONDON GB, pages 224 - 225 *
SPAETE, R.R. ET AL.: "CMV (Towne) glycoprotein H (gH) is complexed with GRP78 and GRP94", PROGRESS IN CYTOMEGALOVIRUS RESEARCH. M.P. LANDINI EDITOR, 1991, ELSEVIER SCIENCE PUBLISHER, pages 133 - 136 *
SPAETE, R.R. ET AL.: "Coexpression of truncated Human Cytomegalovirus gH with UL115 gene product or the truncated Human Fibroblast growth Factor Receptor results in transport of gH to the cell surface", VIROLOGY, vol. 193, no. 2, February 1993 (1993-02-01), pages 853 - 861 *

Also Published As

Publication number Publication date
EP0652966B1 (fr) 2002-09-25
AU4800893A (en) 1994-03-03
DE69332334D1 (de) 2002-10-31
AU680425B2 (en) 1997-07-31
JP3048387B2 (ja) 2000-06-05
DK0652966T3 (da) 2003-02-03
EP1298215A3 (fr) 2007-09-26
EP0652966A1 (fr) 1995-05-17
JPH07509370A (ja) 1995-10-19
WO1994003620A2 (fr) 1994-02-17
EP1298215A2 (fr) 2003-04-02
DE69332334T2 (de) 2003-08-07
US5767250A (en) 1998-06-16
CA2140531C (fr) 2000-03-28
ATE224956T1 (de) 2002-10-15
US5474914A (en) 1995-12-12
CA2140531A1 (fr) 1994-02-17

Similar Documents

Publication Publication Date Title
WO1994003620A3 (fr) Procede permettant d'accroitre l'expression de proteines virales
EP0259475A4 (fr) Facteur recombinant de croissance des cellules endotheliales chez l'homme.
EP0433371A4 (en) Fusion protein of paramyxovirus, method of production using recombinant baculovirus expression vector, vaccine comprising such protein and use thereof
CA2054699A1 (fr) Production du facteur de croissance des cellules endotheliales vasculaires et adn l'encodant
CA2189882A1 (fr) Vaccins contre le papillomavirus
CA2134094A1 (fr) Production de lactoferrine humaine recombinante
AU573523B2 (en) Functional human urokinase proteins
IE883612L (en) Vectors and compounds for direct expression of activated human protein c
CA2149319A1 (fr) Proteine de la membrane externe d'haemophilus
CA2089094A1 (fr) Expression de polypeptides recombinants et methode de purification amelioree
EP0732340A3 (fr) Expression dans la même cellule de polypeptides du virus du syndrome reproductif et respiratoire porcin
CA2036894A1 (fr) Vecteurs et composes pour l'expression de mutants de la proteine c humaine obtenus par glycosylation
AU7635887A (en) Recombinant HTLV-III proteins and uses thereof
AU7440087A (en) Process for isolating and purifying p. falciparum cs protein vaccine expressed in recombinant e. coli
CA2031354A1 (fr) Methode de stabilisation des proteines de surface recombinantes du virus de l'hepatite b a partir de levure
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
EP0204302A3 (fr) Laminine et sa préparation
ES8605296A1 (es) Procedimiento de producir factor viii-r humano
AU7963487A (en) Recombinant ligninase
DE68928061D1 (de) Expression von proteinsüssmitteln in hefe
IE850208L (en) Cloned gene in yeast.
AU4504793A (en) Method for preparing membrane proteins and preserving their oligomeric structures under denaturing conditions, and uses of said proteins in diagnostics and vaccination
GB2205568B (en) Recombinant plasmids and silk-like proteins produced therefrom
NO910331D0 (no) Rekombinant plasmid, fremgangsmaate til dets fremstilling og anvendelse av plasmidet i produksjonen av proteiner.
ZA897509B (en) Novel hiv proteins and peptides useful in the diagnosis,prophylaxis or therapy of aids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1993918614

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2140531

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1993918614

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1993918614

Country of ref document: EP